|Security Type||ETF||Mutual fund|
|Segment||Equity: Global Ex-U.S. - Total Market Growth||Specialty: Health|
|Management Style||passive (index-based)||active|
The Fund seeks long-term capital appreciation above international benchmarks such as the MSCI EAFE Index and the BNY Mellon Classic ADR Index. The Fund selects a portfolio of U.S. traded securities of non-U.S. organizations, most often American Depositary Receipts (ADRs), included in the BNY Mellon Classic ADR Index.
AADR performance & returns
Top 10 Holdings (38.80% of Total Assets)
|ASML Holding NV ADR||ASML||5.52%|
|BioNTech SE ADR||BNTX.DE||4.57%|
|LVMH Moet Hennessy Louis Vuitton SE ADR||LVMUY.PA||4.16%|
|Himax Technologies Inc ADR||HIMX||3.79%|
|Sibanye Stillwater Ltd ADR||SBSW.JO||3.64%|
|Logitech International SA||LOGN||3.51%|
|Cemex SAB de CV ADR||CX.MX||3.22%|
|Embraer SA ADR||ERJ.SA||3.06%|
AADR prosNone that we could think of.
AADR consNone that we could think of.
Other relevant AADR comparisons
You may also want to check out the following AADR comparisons that investors often look for on Finny
CGSLX performance & returns
Top 10 Holdings (52.27% of Total Assets)
|Merck & Co Inc||MRK||7.53%|
|UnitedHealth Group Inc||UNH||6.97%|
|Roche Holding AG Dividend Right Cert.||RHHVF||5.70%|
|Thermo Fisher Scientific Inc||TMO||3.67%|
|Alexion Pharmaceuticals Inc||ALXN||3.57%|
The following are CGSLX strengths from our perspective:
- Good news: this fund does not have 12b1, front-end or back-end sales fees.
The following are CGSLX weaknesses from our perspective:
- CGSLX net assets are $0.00 million. This fund is not a popular choice with retail investors.
Other relevant CGSLX comparisons
You may also want to check out the following CGSLX comparisons that investors often look for on Finny
- CGSLX vs AHSAX
- CGSLX vs AHSCX
- CGSLX vs FSPHX
- CGSLX vs ETIHX
- CGSLX vs ETNHX
- CGSLX vs FBDIX
- CGSLX vs FBIOX
- CGSLX vs FBTIX
- CGSLX vs FHCIX
- CGSLX vs FPHAX